Medically reviewed by Drugs.com. Last updated on Mar 28, 2019.
Applies to the following strengths: 0.5 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Benign Prostatic Hyperplasia
0.5 mg orally once a day
Use: Treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to reduce the risk of acute urinary retention (AUR) and BPH-related surgery.
Renal Dose Adjustments
No adjustment recommended.
Liver Dose Adjustments
Dose adjustment may be required as drug exposure could be higher in hepatically-impaired patients due to this drug being extensively metabolized; however, no specific guidelines have been suggested. Caution is recommended.
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Data not available.
-This drug may be taken with or without food.
-Drug capsules should be swallowed whole and not chewed or opened as contact with the capsule contents may result in irritation of the oropharyngeal mucosa.
-This drug is not approved for the prevention of prostate cancer.
-It may take up to 6 months before a treatment response with this drug can be achieved.
-Serum levels of this drug are detectable for 4 to 6 months after treatment cessation.
-Hair loss reduction and induction of hair growth in patients with male pattern hair loss may occur with the use of 5 alpha-reductase inhibitors.
-Overdosage: There is no specific antidote; symptomatic and supportive treatment should be given as appropriate and the long half-life of this drug should be taken into consideration.
Oncology: New PSA baseline (after 3 months of treatment); digital rectal examination and PSA testing (regularly during treatment)
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about dutasteride
- Side Effects
- During Pregnancy
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- 44 Reviews
- Drug class: 5-alpha-reductase inhibitors
- FDA Alerts (1)
Other brands: Avodart